News

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.

Regulatory clearances and approvals continue as agencies work to disseminate literature, raise awareness, redouble research efforts, and improve the efficacy of clinical trials.

Treatments for autoimmune diseases, multiple cancers, and skin blistering have been recommended for marketing approval.

Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes in an interview with Pharmaceutical Technology®.

Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.

While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.

Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.

Seladelpar, which is marketed in the US as Livdelzi, was recommended for an orphan drug designation by CHMP in December 2024.

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

A capsule formulation may offer more consistent and reliable uptake versus a syringe, while being less dependent on food intake.

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

Pharmaceutical Technology® chatted with Preeya Beczek, managing director and co-founder of Beczek.COM, about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.

Benjamin McLeod, Abhi Naravane, PhD, MBA, and Marianna Tcherpakov PhD go behind the headlines to talk about the latest big acquisitions, GLP-1 Super Bowl advertising, and changes in NIH funding.

Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.

The agency has received certification with the Eco-Management and Audit Scheme for its commitment to environmental sustainability.

The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.

The pledge signifies ArisGlobal’s commitment to upholding high standards and best practices for the responsible use of artificial intelligence.

Agnes Cwienczek, director of Product Management at ArisGlobal, talks with Pharmaceutical Technology® about how careers for women in STEM fields can be nurtured.

Pharmaceutical Technology® spoke with Sabine Gölden, eLearning & Training Lead at MAIN5, about her experience working in the pharmaceutical industry.

In seeking a data-driven approach to efficient drug development, MMS aims to enhance its capabilities in advanced clinical trial design, innovative statistics, and data science with the acquisition.

In this exclusive Drug Digest video interview Anil Kane from Thermo Fisher Scientific will be tackling the topic of advances in small-molecule manufacturing and several other experts will provide brief commentaries on associated topics.

This site was previously the beneficiary of a €7.3 million (US$7.6 million) investment, made in 2022, earmarked for the production of HPAPIs to treat cancer.

With the approval, FDA granted SpringWorks a rare pediatric disease priority review voucher.

Investing in STEM programs for girls in an education setting and then supporting women as they excel in their professional careers is key to ensuring that vital highly skilled personnel are not left behind.

Acoramidis was approved by FDA in November 2024 and is prescribed in the US under the brand name Attruby.

Pharmaceutical Technology® sat down with Jean Redmond, Chief Operating Officer at Biologit, to discuss the use of artificial intelligence in pharmaceutical research and development and the role women play in this fast-developing area.

The company says it is the pharmaceutical market’s first wet granulator with an integrated, truly continuous dryer.

While this approval addresses breast cancer, olaparib in combination with durvalumab was approved by the EU in August 2024 for treatment of endometrial cancer.